ArticleRadiation oncology (London, England)2017
Application of the new 8th TNM staging system for non-small cell lung cancer: treated with curative concurrent chemoradiotherapy.
Article in Radiation oncology (London, England), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Clinical features and prognostic nomogram development for cancer-specific death in patients with dual primary lung cancer: a population-based study from SEER database.Journal of cardiothoracic surgery · 2025Article
- Machine Learning in Diagnosis and Prognosis of Lung Cancer by PET-CT.Cancer management and research · 2024Review
- Extended resections in the treatment of locally advanced lung cancer.Turk gogus kalp damar cerrahisi dergisi · 2023Article
- Early recurrence factors in patients with stage III non-small cell lung cancer treated with concurrent chemoradiotherapy.Thoracic cancer · 2022Article
- CHMP4C regulates lung squamous carcinogenesis and progression through cell cycle pathway.Journal of thoracic disease · 2021Article
- Comprehensive genomic profile of Chinese lung cancer patients and mutation characteristics of individuals resistant to icotinib/gefitinib.Scientific reports · 2020Article
- Predictive and prognostic significance of M descriptors of the 8th TNM classification for advanced NSCLC patients treated with immune checkpoint inhibitors.Translational lung cancer research · 2020Article
- Chemoradioimmunotherapy of inoperable stage III non-small cell lung cancer: immunological rationale and current clinical trials establishing a novel multimodal strategy.Radiation oncology (London, England) · 2020Review
- Prognostic value of PD-L1 expression on tumor cells combined with CD8+ TIL density in patients with locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy.Radiation oncology (London, England) · 2020Article
- Development of a Survival Prognostic Model for Non-small Cell Lung Cancer.Frontiers in oncology · 2020Article
- Comment on an external validation of the 8th edition of the TNM classification for lung cancer staging in patients treated with chemoradiation.Annals of translational medicine · 2019Article
- Adjuvant Chemotherapy Following Surgical Resection Improves Survival in Patients With Early Stage Small Cell Lung Cancer.Oncology research · 2019Article
- Identification of seven-gene signature for prediction of lung squamous cell carcinoma.OncoTargets and therapy · 2019Article
- The 8Quantitative imaging in medicine and surgery · 2018Review
- Association of serum follistatin levels with histological types and progression of tumor in human lung cancer.Cancer cell international · 2018Article
- Bordetella bronchiseptica pneumonia in a patient with lung cancer; a case report of a rare infection.BMC infectious diseases · 2017Article
- Diagnosis of lung cancer by flexible fiberoptic bronchoscopy: a descriptive study.Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologieArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe eighth tumor, node, metastasis (TNM) staging system (8-TNM) for non-small cell lung cancer (NSCLC) was newly released in 2015. This system had limitation because most patients included in the analysis were treated with surgery. Therefore, it might be difficult to reflect prognosis of patients treated with curative concurrent chemoradiotherapy (CCRT). Purpose of this study was to investigate clinical impact of the newly published 8-TNM compared to the current seventh TNM staging system (7-TNM) for locally advanced NSCLC patients treated with CCRT.
methodsNew 8-TNM was applied to 64 patients with locally advanced NSCLC who were treated with CCRT from 2010 to 2015. Changes in T category and stage group by 8-TNM were recorded and patterns of change were evaluated. Survival was analyzed according to T category, N category, and stage group in each staging system, respectively.
resultsAmong the total of 64 patients, 38 (59.4%) patients showed change in T category while 22 (34.4%) patients showed change in stage group using 8-TNM compared to 7-TNM. Survival curves were significantly separated in the 8-TNM stage group (p = 0.001) than those in the 7-TNM (p > 0.05). Especially, survival of newly introduced stage IIIC by 8-TNM was significantly lower than that of others. On the other hand, there was no significant survival difference between T categories in each staging system.
conclusionsSubdivision of stage III into IIIA, IIIB, and IIIC by 8-TNM for patients treated with CCRT better reflected prognosis than 7-TNM. However, subdivision of T category according to tumor size in 8-TNM might be less significant.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.